Stock Analiz

iBio, Inc. IBIO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.73Market cap $52M
Open the interactive analysis →

iBio, Inc. (IBIO) is a healthcare company listed in the US with a market value of about $52M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$35M, a net margin of -3244.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -47% a year, a 5-year average ROIC of -58%.

About iBio

iBio is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $948000 in 2016 to $100000 in 2026, a decline of about 20.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 16903% over three years (dilution for shareholders). It spends 19643% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S48.0
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-53.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-75.0%
Revenue growth (5 yrs, per year)-46.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-12844.5%
ROIC (5-yr avg.)-58.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$1M$100000$400000$225000$0$2M$2M$2M$2M$444000$394000
Net income-$35M-$33M-$18M-$25M-$65M-$50M-$23M-$16M-$18M-$16M-$15M
Free cash flow-$28M-$24M-$15M-$19M-$36M-$45M-$35M-$14M-$15M-$14M-$14M
EPS (diluted)$-0.47$-0.32$-1.75$-6.50$-106.19$-115.65$-60.02$-12.20$-18.81$-30.81$-32.81
Net margin-3244.2%-33044.0%-4594.2%-11069.8%—-2670.0%-978.8%-1003.6%-871.8%-3627.2%-3688.3%
ROIC—-40.0%-101.5%-51.7%-72.3%-26.3%-22.5%-19.3%-506.4%-69.5%-126.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does iBio pay a dividend?

Not currently.

Is iBio a good stock to buy?

We do not give buy or sell advice. iBio scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.